Last reviewed 2026-04-23 · How we verify

VVN461 Ophthalmic Solution 1.0%

VVN461 is an ophthalmic solution designed to treat ocular surface disease by modulating inflammatory pathways in the eye.

VVN461 is an ophthalmic solution designed to treat ocular surface disease by modulating inflammatory pathways in the eye. Used for Ocular surface disease (specific indication not publicly detailed).

At a glance

Mechanism of action

While the exact molecular target is not publicly disclosed, VVN461 is being developed as a topical ophthalmic agent for phase 3 evaluation. As a 1.0% solution formulation, it is intended for direct ocular surface application to address inflammatory or degenerative eye conditions. The specific mechanism likely involves modulation of immune or inflammatory mediators at the ocular surface.

Approved indications

• Ocular surface disease (specific indication not publicly detailed)

Common side effects

No common side effects on file.

Key clinical trials

• A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis (PHASE3)
• Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery (PHASE2)
• Pharmacokinetics of VVN461 Ophthalmic Solution (PHASE1)
• A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• VVN461 Ophthalmic Solution 1.0% CI brief — competitive landscape report
• VVN461 Ophthalmic Solution 1.0% updates RSS · CI watch RSS
• VivaVision Biotech, Inc portfolio CI